REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD

ROCKVILLE, Md, Oct. 3, 2022. REGENXBIO Inc. today announced a program update from its ongoing clinical investigation of RGX-314 for the treatment of wet AMD, a leading cause of vision loss globally. REGENXBIO announced positive interim data from...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials